NEWS & MEDIA
Read our recent announcements
Press
October 26, 2026
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
Read more
Press
Presentation
Announcement
March 28, 2024
Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting
Read more
Press
Announcement
March 27, 2024
Iambic Therapeutics Announces First Patient Dosed in Phase 1 Clinical Study of IAM1363, a Highly Selective HER2 Inhibitor for the Treatment of Solid Tumors
Read more
Press
Announcement
March 18, 2024
Iambic’s Rapid Path to the Clinic Enabled by Its AI-Driven Drug Discovery Platform, Built in Collaboration with NVIDIA
Read more
Publication
February 23, 2024
Iambic Therapeutics Announces New Research with Cover Article in Nature Machine Intelligence Demonstrating the Capabilities of its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures
Read more
Press
Announcement
February 14, 2024
Iambic says new AI model bests AlphaFold as protein models rocket ahead
Read more
Press
Announcement
February 12, 2024
Iambic Therapeutics Announces New Research with Cover Article in Nature Machine Intelligence Demonstrating the Capabilities of its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures
Read more
Press
February 12, 2024
Transforming Computational Drug Discovery with NeuralPLexer2
Read more
Press
February 9, 2024
Iambic Therapeutics expands leadership team with the appointment of Neil Josephson, MD as Chief Medical Officer
Read more
Press
February 7, 2024
Iambic Moves into New HQ
Read more
.png)
Better technology for better medicines
GET IN TOUCH
contact@iambic.ai
(619) 330-5499
Copyright © 2026 Iambic Therapeutics, Inc. All Rights Reserved.